VIT 2763

Drug Profile

VIT 2763

Alternative Names: VIT 2763

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vifor Pharma
  • Class Antianaemics; Small molecules
  • Mechanism of Action Cation transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Iron overload

Most Recent Events

  • 15 Mar 2018 Phase-I clinical trials (In volunteers) in Iron overload (Prevention) in Switzerland (PO)
  • 08 Feb 2018 Vifor Pharma plans a phase I trial (In volunteers) for Iron overload (Prevention) in March 2018
  • 19 Dec 2017 Clinical Trial Application was approved for phase I trial of VIT 2763 for Iron overload (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top